Table 1. Characteristics and incidence rate of newly reported patients with MG (2007–2017).
| Parameters at the first diagnosis | Total No. (%) of new patients with MG | Incidence per 100,000 (95% CI) | Treatment (TMZ or operation) (%) | Use of TMZ (%) | Operation (%) | |
|---|---|---|---|---|---|---|
| Total | 45,066 | 7.47 (7.39–7.53) | 46.3 | 13.8 | 45.5 | |
| Age, yr | ||||||
| 0–19 | 4,006 (8.9) | 2.96 (2.86–3.05) | 64.4 | 7.6 | 61.7 | |
| 20–39 | 5,783 (12.8) | 3.12 (3.05–3.21) | 60.1 | 13.6 | 59.1 | |
| 40–64 | 19,066 (42.3) | 8.78 (8.67–8.91) | 51.5 | 18.1 | 50.9 | |
| ≥ 65 | 16,211 (36.0) | 2.42 (2.38–2.45) | 30.7 | 10.3 | 30.3 | |
| Sex | ||||||
| Male | 23,725 (52.7) | 7.84 (7.74–7.94) | 47.6 | 14.6 | 46.8 | |
| Female | 21,341 (47.3) | 7.09 (6.99–7.19) | 44.8 | 12.9 | 44.0 | |
| Region | ||||||
| Metropolitan | 25,943 (57.6) | 7.12 (7.04–7.21) | 48.4 | 14.9 | 47.5 | |
| City | 13,389 (29.7) | 7.88 (7.75–8.02) | 44.8 | 13.0 | 44.0 | |
| Rural | 5,734 (12.7) | 8.31 (8.08–8.54) | 40.5 | 10.9 | 40.0 | |
| Income | ||||||
| Low | 12,567 (27.9) | 7.55 (7.42–7.68) | 43.7 | 12.3 | 42.8 | |
| Middle | 19,976 (44.3) | 7.39 (7.29–7.50) | 48.0 | 14.0 | 47.3 | |
| High | 12,523 (27.8) | 7.49 (7.35–7.63) | 46.2 | 14.9 | 45.3 | |
MG = malignant glioma, CI = confidence interval, TMZ = temozolomide.